Completed
Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
NCT00567359
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
- Locations
-
- Stanford University Stanford, California, United States
- Massachusetts General Hosptial Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
- Dana-Farber Cancer Institute Boston, Massachusetts, United States